Ratings by Roth/MKM (Boobalan Pachaiyappan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/5/2026 | Coya Therapeutics | COYA | New Coverage | Buy (N/A) |
4.64 (5.64) |
21.55% | Details | |
| 3/19/2026 | Ovid Therapeutics Inc | OVID | Maintain | Buy (N/A) |
|
Details | ||
| 3/18/2026 | CervoMed | CRVO | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2026 | NeuroSense Therapeutics Ltd. | NRSN | New Coverage | Buy (N/A) |
0.87 (0.69) |
-20.69% | Details | |
| 1/9/2026 | LB Pharmaceuticals Inc | LBRX | New Coverage | Buy (N/A) |
20.99 (33.08) |
57.6% | Details | |
| 12/22/2025 | Gain Therapeutics | GANX | Maintain | Buy (N/A) |
|
Details | ||
| 12/11/2025 | Ovid Therapeutics Inc | OVID | New Coverage | Buy (N/A) |
1.57 (2.69) |
71.34% | Details | |
| 11/7/2025 | Immunic Inc. | IMUX | New Coverage | Buy (N/A) |
0.72 (14.69) |
1940.28% | Details | |
| 10/27/2025 | Avidity Biosciences | RNA | Downgrade | Neutral (Buy) |
49.15 (13.45) |
-72.63% | Details | |
| 9/17/2025 | Avidity Biosciences | RNA | New Coverage | Buy (N/A) |
40.22 (49.15) |
22.2% | Details | |
| 8/7/2025 | Entrada Therapeutics | TRDA | Maintain | Buy (N/A) |
|
Details | ||
| 7/14/2025 | Capricor Therapeutics | CAPR | Maintain | Buy (N/A) |
|
Details | ||
| 6/24/2025 | Capricor Therapeutics | CAPR | Maintain | Buy (N/A) |
|
Details | ||
| 5/20/2025 | Capricor Therapeutics | CAPR | New Coverage | Buy (N/A) |
9.44 (22.95) |
143.11% | Details | |
| 3/24/2025 | Entrada Therapeutics | TRDA | Maintain | Buy (N/A) |
|
Details | ||
| 3/18/2025 | CervoMed | CRVO | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2025 | CervoMed | CRVO | Maintain | Buy (N/A) |
|
Details | ||
| 1/10/2025 | Reviva Pharmaceuticals | RVPH | New Coverage | Buy (N/A) |
2.00 (0.35) |
-82.5% | Details | |
| 12/5/2024 | Longeveron | LGVN | New Coverage | Buy (N/A) |
2.00 (0.68) |
-66% | Details |
